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Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and hospital
admission in infants. An analogous disease occurs in cattle and costs US agriculture a bil-
lion dollars a year. RSV causes much of its morbidity indirectly via adverse effects of the
host response to the virus. RSV is accompanied by elevated prostaglandin E2 (PGE2)
which is followed by neutrophil led inflammation in the lung. Ibuprofen is a prototypical non-
steroidal anti-inflammatory drug that decreases PGE2 levels by inhibiting cyclooxygenase.
Hypotheses
We hypothesized that treatment of RSV with ibuprofen would decrease PGE2 levels, modu-
late the immune response, decrease clinical illness, and decrease the histopathological
lung changes in a bovine model of RSV. We further hypothesized that viral replication
would be unaffected.
Methods
We performed a randomized placebo controlled trial of ibuprofen in 16 outbred Holstein
calves that we infected with RSV. We measured clinical scores, cyclooxygenase, lipoxy-
genase and endocannabinoid products in plasma and mediastinal lymph nodes and inter-
leukin (Il)-4, Il-13, Il-17 and interferon-γ in mediastinal lymph nodes. RSV shedding was
measured daily and nasal Il-6, Il-8 and Il-17 every other day. The calves were necropsied
on Day 10 post inoculation and histology performed.
PLOS ONE | DOI:10.1371/journal.pone.0152913 April 13, 2016 1 / 20
a11111
OPEN ACCESS
Citation:Walsh P, Behrens N, Carvallo Chaigneau
FR, McEligot H, Agrawal K, Newman JW, et al.
(2016) A Randomized Placebo Controlled Trial of
Ibuprofen for Respiratory Syncytial Virus Infection in a
Bovine Model. PLoS ONE 11(4): e0152913.
doi:10.1371/journal.pone.0152913
Editor: John S Tregoning, Imperial College London,
UNITED KINGDOM
Received: January 8, 2016
Accepted: March 21, 2016
Published: April 13, 2016
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This study was funded by Award
5K12HL108964-02 from the National Heart, Lung,
and Blood Institute at the National Institutes of Health
(NIH) and by the Pediatric Emergency Medicine
Research Foundation, Long Beach, California.
Additional support was provided by the USDA
Intramural Projects 5306-51530-019-00D and 2032-
5130-022-00D, and the West Coast Metabolomics
Center Grant NIH U24 DK097154. The USDA is an
equal opportunity provider and employer.
Results
One calf in the ibuprofen group required euthanasia on Day 8 of infection for respiratory dis-
tress. Clinical scores (p<0.01) and weight gain (p = 0.08) seemed better in the ibuprofen
group. Ibuprofen decreased cyclooxygenase, lipoxygenase, and cytochrome P450 prod-
ucts, and increased monoacylglycerols in lung lymph nodes. Ibuprofen modulated the
immune response as measured by narrowed range of observed Il-13, Il-17 and IFN-γ gene
expression in mediastinal lymph nodes. Lung histology was not different between groups,
and viral shedding was increased in calves randomized to ibuprofen.
Conclusions
Ibuprofen decreased PGE2, modulated the immune response, and improved clinical out-
comes. However lung histopathology was not affected and viral shedding was increased.
Introduction
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis in infants. The
clinical manifestations largely reflect the hosts’ immune response to RSV; authors have
described eicosanoid and cytokine storms leading to neutrophilic infiltration and tissue destruc-
tion. Antibodies formed to bystander antigens lead to bronchospasm on subsequent re-expo-
sure.[1] Eicosanoid pathway products in general, and prostaglandin E2 (PGE2) in particular are
higher in more severe RSV infection in infants.[2] PGE2 is produced by cyclooxygenase (COX)-
2 in respiratory epithelial cells in response to RSV infection.[3] Multiple COX- and lipoxygenase
(LOX)-generated mediators stimulate the cytokine responses affecting neutrophil and monocyte
trafficking as well as stimulation of mucus secretion from bronchial goblet cells.[4–6]
COX-1 is constitutive, but COX-2 is mostly inducible in the lung;[7] and COX-2 in particu-
lar is believed responsible for the production of prostaglandins and thromboxanes in RSV.[8]
Simple nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen inhibit COX-2 and
to a lesser extent COX-1. Ibuprofen is inexpensive and widely available for human use. Current
treatment of human RSV bronchiolitis is mostly symptomatic and supportive with modest
benefit from bronchodilators in some patients, but not from glucocorticoids or leukotriene
inhibitors.[9–12] NSAIDs are not currently used in human RSV and aspirin is contraindicated
in infants.[13, 14] However pretreatment of RSV infected cotton rats with indomethacin
decreases the severity of lung histology,[15] and in veterinary medicine NSAIDs are used as
adjuncts to antibiotics in mixed respiratory infections in cattle and piglets.[16–18] A random-
ized controlled trial (RCT) in asthmatic children found that ibuprofen, compared with acet-
aminophen, decreased near term wheezing following viral upper respiratory tract infection
(URI)[19] and ibuprofen decreases antibody production in human monocytes.[20]
The outbred Holstein bovine model of RSV bronchiolitis uses a naturally occurring bovine
RSV to replicate the clinical, immunological, and histological features of human RSV. This
model has good applicability to human infants and has replicated the enhanced disease
observed in formalin killed RSV vaccine.[21]
We hypothesized that treatment of RSV with ibuprofen would decrease systemic PGE2 lev-
els, modulate the immune response, decrease clinical illness, and decrease the histopathological
lung changes in a bovine model of RSV. We further hypothesized that viral replication would
be unaffected. These hypotheses were tested in a placebo controlled RCT.
Ibuprofen in RSV Infection
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Materials and Methods
We performed an RCT using a bovine model to test the hypothesis that ibuprofen would
decrease the severity of RSV bronchiolitis. The University of California Davis Institutional Ani-
mal Care and Use Committee approved this study (Protocol #17771).
Subjects
Sixteen five to six week-old outbred pre-ruminant bottle-fed Holstein bull calves.
Intervention
Following a week of observation to ensure they were disease free, calves were experimentally
infected with 5 mL of 1.5 X 10^5/ml (by TCID50) bovine RSV using a tightly fitting mask with
an attached nebulizer.[21, 22] The calves were randomized to receive either ibuprofen 10mg/kg
three times daily or identical appearing and tasting placebo administered in milk replacer. This
dose is the same as is typically used in children (10 mg/kg tid) and is similar dosing that has
previously been used in cattle. Randomization was performed using a minimization strategy
based first on maternal RSV antibody titres (determined by indirect immunofluorescence) and
then body weight. All animals were housed in climate controlled barns at our veterinary school.
Free access to water and a small amount of oat hay was allowed.
Measurement of clinical scores
A complete physical exam was performed at 07:00 daily, with additional respiratory exams and
temperature measurements at 13:00 and 19:00. These findings were used to calculate a daily
clinical severity of illness score. This score was originally developed by Collie et al [23] and has
been widely used subsequently. A modified version which underweights the importance of
fever has also been described,[22] and because of the antipyretic effects of ibuprofen, that is the
version we used. The scoring schema is in supporting information (S1 Table). The veterinarian
and physician doing evaluations and their research assistants were blinded to drug allocation.
The calves were weighed at the start and the end of the experiment. On day 10 post infection
the calves were euthanized with pentobarbital overdose and necropsied.
Measurement of the eicosanoid, thromboxane, lipoxygenase and
endocannabinoid pathway products
Lipid mediators of immune function were quantified using liquid chromatography with tan-
dem mass spectrometry (LC-MS/MS) in plasma collected on day 0, 3, 7, and 10 of infection,
and terminally collected lymph tissue. Measured mediators included oxylipins derived from
cyclooxygenase, lipoxygenase, and cytochrome P450 dependent metabolism, as well as the
endocannabinoid and endocannabinoid-like monoacylglycerols and acylethanolamides.
Plasma (100μL) and lymph tissue (~20–30mg) were enriched with a suite of deuterated surro-
gates prior to extraction.[24] Plasma samples were extracted directly with 300μL acetonitrile
with 1% formic acid while tissues were first cryopulverized with 50μL of methanol in a Geno/
Grinder 2000 (SPEX SamplePrep; Metuchen, NJ) at 1350 rpm for 90 seconds in 30 second
increments, and extracted by further pulverization with 550μL acetonitrile with 1% formic
acid, and 100μL water for 90 seconds. Supernatants were isolated by centrifugation. Target ana-
lytes were isolated in extract eluents from an Ostro Sample Preparation Plate (Waters Corp;
Milford, MA), concentrated into 2μL of glycerol, and reconstituted in an internal standard
solution containing 1-cyclohexyl-3-ureido dodecanoic acid and 1-phenyl,3-ureido hexanoic
acid in 1:1 (v/v) methanol:acetonitrile prior to analysis.[24]
Ibuprofen in RSV Infection
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Analytical targets were separated on a 2.1 x 150 mm, 1.7 μm BEH C18 column (Waters; Mil-
ford, MA) and detected by positive or negative mode electrospray ionization (endocannabi-
noids or oxylipins, respectively) and tandem mass spectrometry on an API 4000QTrap (Sciex;
Framingham, MA).[24] Calibrants and internal standards were from Cayman Chemical (Ann
Arbor, MI), or Avanti Polar Lipids Inc. (Alabaster, AL). Larodan Fine Lipids (Malmo, Sweden)
provided the linoleate-derived triols 9,12,13-TriHOME and 9,10,13- TriHOME. Data was pro-
cessed utilizing AB Sciex MultiQuant version 3.0.2.
Measurement immunological profiles
Expression of interferon-γ (IFN-γ), interleukin (Il)-4, Il-17, and Il-13 was measured by real-
time TaqMan RT-PCR in mediastinal lymph nodes. Expression of Il-6, Il-8 and Il-17 was also
evaluated in nasal secretions as this type of sample will be readily accessible in human transla-
tion. For each gene, two primers and an internal, fluorescent labeled Roche Universal Probe
Library probe was designed using Primer Express software (Applied Biosystems, Foster City,
CA). Cell pellet samples were placed in 470μL of Buffer RLT+Isopropanol and 40uL Proteinase
K Enzyme, heated at 56°C for 30 minutes, and stored at -20°C. Two grinding beads (4 mm
diameter, stainless steel beads, SpexCertiprep, Metuchen, NJ) were added and the tissues
homogenized in a GenoGrinder2000 (SpexCertiprep) for 2.5 minutes at 1000 strokes per min-
ute. Total RNA was extracted from the tissue lysates using a BioSprint automated nucleic acid
(ANA) workstation (Qiagen) according to the manufacturer’s instructions for the One-for-all
Vet Kit (Qiagen).
The Quantitect Reverse transcription kit (Qiagen) was used for cDNA synthesis following
the manufactures directions with the following modifications. Ten microliters of RNA were
digested with 1μL of gDNAWipeOut Buffer by incubation at 42°C for five minutes and then
briefly centrifuged. Genomic DNA contamination was tested by using 1μL of digested RNA and
running the real-time PCR housekeeping gene. Then 0.5 μL of Quantitect Reverse Transcriptase,
2μL Quantitect RT buffer, 0.5μL RT Primer Mix, 0.5μL 20 pmol Random Primers (Invitrogen)
were added and brought up to a final volume of 20μL and incubated at 42°C for 40 minutes.
The samples were inactivated at 95°C for 3 minutes, chilled, and 80μL of water was added.
Final quantitation was done using the comparative CT method (User Bulletin #2, Applied
Biosystems) and is reported as relative transcription or the n-fold difference relative to a cali-
brator cDNA (i.e. lowest target gene transcription). In brief, the three reference genes were
averaged to normalize the CT values of the target genes (ΔCT). The ΔCT was calibrated against
the average of the negative control group within each target gene. The linear amount of target
molecules relative to the calibrator was calculated by 2-ΔΔCt and gene transcription is expressed
as an n-fold difference relative to the calibrator.
Measurement of histopathology
Lung consolidation was estimated by inspection by an experienced board certified veterinary
pathologist. Sections of the right lung were collected and fixed for at least 24 hours in 10% for-
malin. The left lung was then perfused with formalin at 15 cm water pressure. A second board
certified veterinary pathologist blinded to the gross autopsy findings performed detailed histo-
logical assessment of the slides. Both pathologists were blinded to drug assignment. A scoring
system (S2 Table) was derived from the placebo group and validated on weight change and clin-
ical findings. This scoring system was then applied to both groups. The scoring system is
described in detail elsewhere. Briefly it comprises three components: a semi-quantitative esti-
mate of percentage lung consolidation; a semi-quantitative estimate of acute inflammatory pro-
cesses as evidenced by neutrophilic infiltrates, transmigration of neutrophils into the bronchial
Ibuprofen in RSV Infection
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and bronchiolar lumen, and septal thickening with edema and cellular exudate; and a semi-
quantitative estimate of sub-acute lung inflammation as evidence by mononuclear cell infil-
trates. The histopathological scoring system is described in detail in the supporting information
files. We also compared the associations between each of these components by treatment group.
Measurement of viral shedding
We took nasal swabs daily and quantitated viral shedding with RT-PCR. Total RNA was
extracted from the cell lysate from calf nasal swabs collected and stored in lysis buffer (Life
Technologies, NY), using the Pure Link RNA min kit (Life Technologies, NY), according the
manufactures directions.
Extracted RNA was stored at -80°C until use. Viral cDNA was synthesized by using Super-
Script III First Strand synthesis system (Invitrogen, CA), according to the manufacturer’s
directions. The cDNA thermocycling program consisted of 10 minutes at 25°C, 50 minutes at
50°C, and a termination cycle of 85°C of 5 minutes. Synthesized cDNA was stored at -20°C.
The Q-RT-PCR was performed in triplicate on a 384-well plate, in a 20uL reaction volume.
The 20uL reaction mixture contained 10uL Sybr green qPCR master mix, 2uL of BRSV-NP-F
primer, (GCAATGCTGCAGGACTAGGTATAAT) 2uL BRSV-NP-R reverse primer (ACACTG
TAATTGATGACCCCATTC), and 2uL nuclease free water. The RT-PCR thermocycling pro-
gram consisted of 48°C for 30 min, 95°C for 5 minutes, followed by 40 cycles of 95°C and 55°C
for 1 minute each. Fluorescence was measured following each cycle and displayed graphically
(AB Applied Biosystems ViiA-7 detection software, version 1.1) The ViiA-7 software deter-
mined a cycle threshold (Ct) value, which identifies the first cycle at which the fluorescence is
detected above the baseline for each sample or standard.
Statistical Methods
Data entry was performed using a customized Filemaker-pro 12 database (Filemaker Inc. Santa
Clara, CA). Serial data was analyzed using mixed effects models. Non-normally distributed var-
iables were compared using rank sum techniques. Categorical variable were compared using
Fisher’s exact test. These tests were performed with Stata 14 (Statacorp LLP, College Station,
TX). All clinical, immunological, and metabolomics data were then included in a partial-least
squares discriminant analysis (PLS-DA), using treatment as the classifier. PLS-DA is a classifi-
cation tool that is widely used when there are more independent variables than study subjects.
This situation commonly arises in studies of lipid mediators and in genetic studies. The multi-
variate analyses and associated normality transformations were performed using imDEV
v1.42, a Microsoft Excel (Microsoft Corporation, Redmond, WA) Add-In interface [25] to the
R-statistical environment (R Foundation for Statistical Computing, Vienna, Austria).
Results and Discussion
Sixteen calves were randomized; 15 completed the protocol as scheduled on day 10. One, in the
ibuprofen group, was euthanized for respiratory distress on day 8. The mean and peak clinical
scores were lower (p<0.001) and the mean weight gain 4 kg higher in the ibuprofen than the
placebo group (p = 0.08 Decreased pyrexia and lower respiratory rates in the ibuprofen group
had the greatest influence on clinical scores. The ibuprofen group had noticeably less sick
behaviour, (depressed, failure to rise, anorexia) than the placebo group. The clinical scores and
time to more severe clinical scores are shown in Fig 1.
Mediastinal lymph node levels of cyclooxygenase-derived products were markedly
decreased in the ibuprofen group, with PGE2>>Thromboxane (TX) B2> PGD2>
9-Hydroxy-10,12-octadecadienoic acid (9-HODE)>>>5,15-dihydroxyeicosatetraenoic acid
Ibuprofen in RSV Infection
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(5,15-DiHETE). Levels of the 12-lipoxygenase product, 12-Hydroxyeicosatetraenoic acid
(12-HETE) were highly variable, but also showed substantial reductions in the ibuprofen
group. Thromboxane A2 and the lipoxygenase pathways were also markedly inhibited in the
ibuprofen group. Fig 2 shows the effect on selected individual components of each pathway.
The complete set of measured mediators is in S3 and S4 Tables.
Ibuprofen’s effect on the cytokine profiles of the bronchial lymph nodes was complex.
Rather than seeing straightforward changes in Th-1/Th-2 skew we observed a generalized
moderation of cytokine expression across IFN-γ, Il-17 and Il-13 functions with respect to each
other and Il-4. Figs 3 and 4 show cytokine expression in the mediastinal lymph nodes of ani-
mals treated with ibuprofen tended towards a narrow range compared with the placebo group.
There was little difference in the gross pathology or histology of the lungs between ibupro-
fen and placebo groups. The gross histology findings are shown in Figs 5 and 6 and overall his-
tological scores are shown in Fig 7.
Viral shedding started on Day 3 in both groups, corresponding to the URI phase in calves
and infants. Viral shedding was increased in the ibuprofen group. This difference became sta-
tistically significant (p<0.001) around the period of peak viral shedding (Fig 8).
Fig 1. Comparison of clinical outcomes in ibuprofen and placebo groups. Sixteen calves were
experimentally infected with bovine respiratory syncytial virus by nebulizer on Day 0. Eight received ibuprofen
and received eight placebo. (A) Shows the mean clinical score by treatment group for each day. The groups
were statistically significantly different by Day 5 using a mixed effects model. (B) Shows the time taken to
enter the most severe decile of illness as measured by the clinical score. Statistical significance was
calculated using the log rank test. (C) Shows the percentage weight gain for each individual calf. Calves
randomized to ibuprofen are in red; placebo is in blue. Statistical significance was calculated using ordinary
least squares regression. (D) Shows the mean temperature by treatment group. Temperature was measured
every eight hours. (E) Shows the mean respiratory rate per group. Respiratory rate was measured every eight
hours. Statistical significance was calculated for both temperature and respiratory rate using a mixed effect
model. (F) Shows the time taken to enter the most severe decile of tachypnea. Statistical significance for (F)
was calculated using the log rank test.
doi:10.1371/journal.pone.0152913.g001
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This difference in viral shedding was accompanied by differences in Il-8 (p = 0.008). The Il-
6 levels showed greater variance and were statistically significantly different only during peak
illness (p = 0.009) as shown in Fig 9. Nasal swab Il-17 was not different between groups at any
time during the experiment.
PLS-DA analysis of metabolomics, cytokine, clinical and histological outcomes discrimi-
nated the treatment groups as seen in Fig 10. Ibuprofen lowered lymph tissue COX and LOX
products, the 1- and 2- oleoylglycerol (OG), clinical scores and pyretic measures, while increas-
ing fatty acid alcohol dehydrogenase products (i.e. fatty acid ketones), and soluble epoxide
Fig 2. Comparison of mediastinal lymph node lipid mediators as measured by mass spectroscopy for
each treatment group. PGE2; Prostaglandin E2, TXB; Thromboxane B2, PGD2; Prostaglandin D2, 12-HETE;
12-Hydroxyeicosatetraenoic acid, 9-HODE; 9-Hydroxy-10,12-octadecadienoic acid (9-HODE),
5,15-DiHETE; 5,15-dihydroxyeicosatetraenoic acid. Ibuprofen is in red, placebo in blue.
doi:10.1371/journal.pone.0152913.g002
Fig 3. Comparison of mean cytokine expression asmeasured by polymerase chain reaction of the
genes required for their production in mediastinal lymph nodes for each treatment group. Ibuprofen is
in red, placebo in blue.
doi:10.1371/journal.pone.0152913.g003
Ibuprofen in RSV Infection
PLOS ONE | DOI:10.1371/journal.pone.0152913 April 13, 2016 7 / 20
hydrolase-derived fatty acid diols (e.g. linoleate derived 12,13-dihydroxyoctadecamonoeneoic
acid; 12,13-DiHOME), and the cytokine Il-13. Plasma concentrations of TXB2 were also
reduced at day 7 and 10, as were numerous fatty acid diols. On day 3, plasma concentrations of
1- and 2-linoleoylglycerol (LG) and the 1- and 2-oleoylglycerol (OG) were significantly
Fig 4. Comparison of the expression of each cytokine (as measured by polymerase chain reaction of the genes required for their production) with
respect to the expression of other cytokines in mediastinal lymph node in ibuprofen and placebo groups.Warmer colors (yellows, reds) on the Z-axis
indicate higher levels, cooler color (greens, blues) indicate lower levels.
doi:10.1371/journal.pone.0152913.g004
Ibuprofen in RSV Infection
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Fig 5. Comparison of histology findings between placebo and ibuprofen treated calves broken down by anatomical levels as follows: alveoli,
bronchioles, and bronchi. These are scored 0 (absent), 1 (mild), 2 (moderate) 3 (severe). The median is indicated by a line and the interquartile range by
the box. Whiskers encompass data 1.5 times the IQR of the upper and lower quartiles. Outlying data is indicated with points. Ibuprofen is in red, placebo in
blue. EOS; eosinophils, Hyperpl; hyperplastic, MN; monocytes, PMN; neutrophils, Pneumo; pneumocytes.
doi:10.1371/journal.pone.0152913.g005
Ibuprofen in RSV Infection
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Fig 6. Comparison of histology findings between placebo and ibuprofen treated calves broken down by anatomical levels as follows: interstitium,
septae, and pleura. These are scored 0 (absent), 1 (mild), 2 (moderate) 3 (severe). The median is indicated by a line and the interquartile range by the box.
Whiskers encompass data 1.5 times the IQR of the upper and lower quartiles. Outlying data is indicated with points. Ibuprofen is in red, placebo in blue. EOS;
eosinophils, Hyperpl; hyperplastic, MN; monocytes, PMN; neutrophils, Pneumo; pneumocytes.
doi:10.1371/journal.pone.0152913.g006
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reduced by ibuprofen treatment. The full mass spectroscopy results are shown for lymph nodes
in S3 Table and for plasma in S4 Table.
Discussion
Ibuprofen decreased PGE2 levels and the range of individual expression of Il-13, Il-17, and IFN-γ
was narrowed. This immunomodulatory effect for ibuprofen was associated with improved clini-
cal but not histological outcomes in a bovine model of RSV bronchiolitis. Paradoxically, we also
found increased RSV shedding and nasal epithelial Il-8 in the ibuprofen group.
Lipid mediators
The rapid release of lipid mediators is an important immunological signaling process that may
be dependent on constitutive COX-1 and COX-2 prior to the further induction of COX-2.[26,
27] The S-enantiomer of ibuprofen inhibits both COX-1 and COX-2 responsible for the pro-
duction of a host of eicosanoids, while the R-enantiomer inhibits fatty acid amide hydrolase,
Fig 7. Comparison of the summary histopathological scores between placebo and ibuprofen treated calves. This summary score includes selected
histological features and amount of lung consolidation. This minimum possible score is 0, the maximum possible is 632. Ibuprofen treated group is in red,
placebo in blue.
doi:10.1371/journal.pone.0152913.g007
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which degrades acyl-ethanolamides, some of which have immunomodulatory activity.[28–33]
Ibuprofen nearly eliminated COX-dependent products in lymph tissues 10 days post infection,
and consistently lowered plasma thromboxane B2 levels late in the infection.
Endocannabinoids are also implicated as immunomodulatory compounds [34]. However,
the measured endocannabinoids and endocannabinoid-like compounds were minimally
affected in this study. While significant changes in acylethanolamides were not observed in
plasma or lymph tissues, on day 7, plasma concentrations oleoyl- linoleoyl- and arachidonoyl-
ethanolamides (i.e. OEA, LEA, AEA) approached a significant change (1-tailed t-test, p< =
0.1) with a calculated effect size of 0.68–0.78 (95%ci ~ -0.1–2.3), and the OEA and LEA aided
in group discrimination.
Lipoxygenases also have important immunomodulatory functions during tissue injury and
repair.[35] Interestingly, 12/15-LOX products were decreased in ibuprofen treated animals,
while no evidence of 5-LOX activation was observed. These findings argues against an increase
in substrate availability due to COX inhibition driving LOXmetabolism,[36] and downstream
leukotrienes[37], and a potential enhancing effect of ibuprofen on PMN 5-LOX.[38] This may
be because of inter-pathway cross talk; the LOX pathways’ enzymes may be positively influenced
by PGE2.[37, 39] We also observed a decrease in cytochrome P450 epoxidase products and an
increase in their sEH-dependent diol products in the ibuprofen group. These findings mirror
those of the effect of ibuprofen in human volunteer studies.[40] Our finding are also in line with
those of Palumbo et al that noted virus dependent activation of COX and LOX12/15, and virus
inhibition of 14,15-dihydroxyeicosatrienoate (14,15-DiHETrE), an sEH dependent diol, in
Fig 8. Mean by treatment group cytokine expression (samples collected by nasal swabbing).
Statistical significance was calculated using a mixed effects mode. Ibuprofen is red, placebo group blue. IL-8
was significantly different between groups. IL-6 demonstrated substantial variance and return to similar levels
between treatment groups over the duration of the experiment. This difference was statistically significant
only at the time of peak difference (p = 0.009). Il-17 was not different between groups at any time during the
experiment.
doi:10.1371/journal.pone.0152913.g008
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cowpox (but not parainfluenza or herpes simplex) infection.[41] The lack of 5-LOX activation is
consistent with the clinical trial findings that montelukast, which blocks the action of leukotri-
ene D4 (a downstream product of 5-LOX), does not improve outcomes in bronchiolitis.
Our data suggest that ibuprofen suppresses this virus dependent activation of lipid media-
tors. This in turn leads to a decreased inflammatory response, which simultaneously increases
viral shedding but decreases clinical illness. We speculate that this provides a biological expla-
nation for why NSAID and aspirin use may decrease subsequent allergen induced wheezing ill-
ness.[19] Aspirin directly decreases COX and indirectly decreases LOX and the prohibition of
its use in infants has been accompanied by an increase in childhood asthma.[42] There is cir-
cumstantial evidence to support this concept. Ibuprofen decreases antibody production in
human cells[20] and RSV infection increases host B-cell and antibody production to bystander
antigens.[43]
PGE2 in nanomolar concentrations can induce Th-17 differentiation through EP2 and EP4
receptors.[44] We also observed a large decrease in 12-HETE in the ibuprofen group;
12-HETE affects neutrophil calcium levels and possibly their migratory response.[45] The pic-
ture is complex because lipid mediators regulate cytokine production and vice versa as leuko-
cytes infiltrate tissue.[46–48, 49]
Cytokines
Experimental evidence supports a conceptual framework in which the Th-2 response to RSV,
which RSV itself accentuates, increases the lung pathology of the initial infection and promotes
the formation of antibodies to bystander antigens and recurrent wheeze.[1, 50] We had antici-
pated that by inhibiting COX-2 with ibuprofen we would drive this skew towards Th-1 with
Fig 9. Themean by treatment group daily viral shedding asmeasured by polymerase chain reaction
of bovine respiratory syncytial virus from nasal swabs. Each sample was tested in duplicate and both
duplicates shown with random jitter added to prevent overlapping of individual measurements. Ibuprofen is
red, placebo blue. Statistical significance was calculated using a mixed effects model. The difference was
statistically significant on post inoculation Days 6 through 8.
doi:10.1371/journal.pone.0152913.g009
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most effect on Il-4/IFN-γ ratios. In fact we observed relatively a narrower range of IFN-γ but
not Il-4 gene expression in the ibuprofen group. Similarly, Il-13 and Il-17 responses to RSV
infection fell within a much narrower range in the ibuprofen group. Il-17 reflects Th-17 activ-
ity. Th-17 is primarily responsible for an increased neutrophilic response and indirectly
increases mucous producing goblet cells via Il-13. Therefore it may be that a goal of treatment
should be to ensure adequate but not excessive Th-17 response to RSV infection.[6] We specu-
late that this may also be the case for Il-13, where some mucous increases respiratory epithe-
lium resilience against infection but excessive amounts lead to mucous plugging and increased
work of breathing.
Vial shedding and nasal epithelial response
In the nasal secretions we observed lower nasal epithelial expression of Il-8 in the ibuprofen
than the placebo group despite higher viral load. Increased levels of Il-8 have been associated
with higher levels of viral replication.[51] Higher levels of Il-8 have also been associated with
increased severity of disease as has higher viral load.[52] However PGE2 increases Il-8 in pul-
monary microvascular endothelium.[53] These findings are consistent with human studies
Fig 10. Partial least squares discriminant analysis (PLS-DA) of measurement from RSV infected calves with and without ibuprofen treatment. The
Scores Plot (Inset) shows treatment group discrimination (ibuprofen: red; placebo: blue). The Loadings Plot shows the discriminant variable weighting with
variables grouped by hierarchical cluster analysis of their Spearman’s correlations. Point shapes describe variable origin (i.e. tissue type or clinical
observation), point colors describe variable class (i.e. metabolite or clinical data type) as described in the figure, and point sizes are defined by the variable
importance in projection (VIP) scores. VIP scores roughly correlate with t-test p-values (small p = 0.12–0.05, medium p<0.05, large p<0.001). Variables to the
right of the origin are elevated in the placebo group. For example, the placebo group shows higher lymph (triangles) and plasma (diamonds) concentrations
of cyclooxygenase (COX) and lipoxygenase (LOX) products, higher plasma thromboxane B2 (TXB2), higher temperatures and plasma concentrations of
soluble epoxide hydrolase (sEH) generated fatty acid diols at the majority of time points, but lower concentrations of fatty acid alcohol dehydrogenase (ADH)
metabolites in lymph tissues and plasma.
doi:10.1371/journal.pone.0152913.g010
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that have also shown an increase in RSV shedding with glucocorticoid treatment.[54, 55] Ibu-
profen simultaneously increased viral load but decreased illness severity as evidenced by weight
gain and clinical scores. This apparent paradox argues for a combined antiviral and immuno-
modulatory approach to RSV.
The balance between direct cytopathology and immune mediated lung damage may differ
between species and individuals. In mice for instance lung damage is primarily immune medi-
ated whereas in cotton rats, cattle, and humans both the virus and host response play a role.
[56, 15, 57] COX inhibition also prolongs rhinovirus shedding in adult humans,[58] and
decreases antibody response when given prior to vaccination.[59]
This data makes the case for an RSV treatment strategy that modestly modulates the
immune response (for example with ibuprofen), while simultaneously giving drugs to prevent
RSV replication. This suggestion is supported by a case report of a 4-month-old -infant with T
cell-natural killer cell-B cell+ severe combined immunodeficiency and persistent RSV infec-
tion. This infant simultaneously demonstrated both a marked decrease in viral shedding and
increase in pulmonary symptoms after immune system reconstitution following bone marrow
transplantation; the viral shedding returned and pulmonary findings improved with immuno-
suppression.[56] Future research should focus on combining antiviral and NSAIDs or other
immunomodulators and determining how late into the course of RSV infection treatment can
be successfully started.
Limitations
The primary limitation of our work from an agricultural stand point is that we started treat-
ment the day of inoculation rather than waiting for clinical symptoms to develop. We did this
because if ibuprofen failed to improve outcomes when given this early then our hypothesis
would have been thoroughly disproven. No further work to determine how late into the course
of illness NSAIDs could be beneficial would be needed. This approach mirrors that taken with
other early stage drug studies. An inherent limitation of the bovine RSV model is the frequent
development of secondary bacterial infections in RSV infected calves. This can be diminished
by pre-treating calves with antibiotics prior to initiation of the viral infection. Secondary bacte-
rial infection occurs less frequently in humans ranging from 20% overall to 44% in those
admitted to the pediatric intensive care unit.[60–62] Consequently our model approximates
the more severe forms of bronchiolitis in infants. This in part reflects our use of a minimally
passaged virus that had demonstrated significant pathogenicity in the wild. Even this limitation
is appropriate; most cases of RSV in both humans and cattle are mild and do not result in a
clinical diagnosis of bronchiolitis. Furthermore pretreatment with antibiotics would decrease
the applicability of our results to veterinary practice. Another limitation is that because we
minimized on maternal anti-RSV antibody titre first and weight second our placebo group was
on average heavier than the placebo group at enrollment. This tends to bias our study against
finding a benefit where one exists. Our sample size was small compared to human RCTs
although typical for large animal studies which are expensive to conduct. Inhibition of COX
was poorly reflected in the plasma, as were systemic changes in lipoxygenase metabolites, dem-
onstrating the difficulty in extrapolating mediator responses in the plasma to changes at the tis-
sue level. Therefore, little information regarding the time course of lipid mediator changes can
be gleaned from this study. This highlights an inherent limitation for human studies where
only nasal secretions and blood can be obtained for testing, but where lung and lymph tissue
are matter more. Our lipidomics findings in plasma however mirror those of human studies
which have examined the effect of ibuprofen in blinded human RCTs.[40] The immunological
validity of the bovine model for RSV has been demonstrated.[21]
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Implications for veterinary and medical practice
These findings generally support the early use of NSAIDS as adjunctive treatment of bovine
RSV which is a key component in bovine respiratory disease complex. The results are not
directly applicable to veterinary practice because our study was designed as a proof of concept
with early drug administration and use of ibuprofen rather than a more widely used veterinary
NSAID. Ibuprofen is short acting and has limited safety data in bovines. [63] The proof of con-
cept design also limits its applicability to pediatrics, but ibuprofen is a widely used NSAID in
pediatrics at the dosage we used. The safety of ibuprofen is well established in children. Our
work does raise the caution that although NSAIDs improve clinical appearance, NSAIDs
increase viral shedding with attendant implications for infection control in dairies and hospitals.
Conclusion
Ibuprofen decreased COX, 12/15-LOX, and cytochrome P450 epoxygenase products in lung
lymph nodes. Ibuprofen modulated the immune response as measured by narrowed range of
observed Il-13, Il-17 and IFN-γ gene expression in mediastinal lymph nodes. Weight and clinical
scores were improved by ibuprofen but lung histology was not, and viral shedding was increased.
This apparent paradox argues for a combined antiviral and immunomodulatory approach to RSV.
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